menu
    • menu
    [{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"68-Ga OncoACP3","moa":"ACP3","graph1":"Oncology","graph2":"Phase I","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"68-Ga OncoCAIX","moa":"CA IX","graph1":"Oncology","graph2":"Phase I","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga OncoFAP","moa":"FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NMS-03597812","moa":"IDH1","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NMS-03597812","moa":"IDH1","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Philogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"IL12-L19L19","moa":"IL-12 \/ tumor vasculature","graph1":"Oncology","graph2":"Phase I","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Philogen \/ Undisclosed"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nerviano Medical Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nerviano Medical Sciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Merck & Co"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMS-03305293

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

                            Details : NMS-03305293 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 17, 2025

                            Lead Product(s) : NMS-03305293

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMS-03305293

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

                            Details : NMS-03305293 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2025

                            Lead Product(s) : NMS-03305293

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga OncoACP3

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer

                            Details : 68-Ga OncoACP3 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : 68-Ga OncoACP3

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga OncoCAIX

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer

                            Details : 68-Ga OncoCAIX is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : 68-Ga OncoCAIX

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMS-03597812

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

                            Details : NMS-03597812 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 12, 2024

                            Lead Product(s) : NMS-03597812

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga OncoFAP

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

                            Details : 68-Ga OncoFAP is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 27, 2023

                            Lead Product(s) : 68-Ga OncoFAP

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMS-03305293

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Scie...

                            Details : NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 21, 2022

                            Lead Product(s) : NMS-03305293

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Philogen

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Pr...

                            Details : Onfekafusp Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Onfekafusp Alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Nerviano Medical Sciences

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMS-03597812

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

                            Details : NMS-03597812 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 30, 2021

                            Lead Product(s) : NMS-03597812

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Fidia Farmaceutici Spa

                            Italy arrow
                            FNCE
                            Not Confirmed

                            Fidia Farmaceutici Spa

                            Italy arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of ONCOFID-P-Bâ„¢ (PACLITAXEL-HYALURONIC ACID)

                            Details : Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 15, 2021

                            Lead Product(s) : Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth